Andeleeb Al Mobaraq Dahy
About Andeleeb Al Mobaraq Dahy
Andeleeb Al Mobaraq-Dahy is the VP of Regulatory Affairs with over 15 years of experience in the pharmaceutical and biotechnology sectors, specializing in global regulatory submissions and drug development strategies.
Professional Background and Experience
Andeleeb Al Mobaraq-Dahy has more than 15 years of experience in the field of Regulatory Affairs, having held key roles in both the pharmaceutical and biotechnology sectors. She has worked with renowned companies such as Astellas, Sanofi/Genzyme, and Novartis/Sandoz, contributing significantly to their regulatory departments. During her tenure, she has been responsible for multiple successful submissions to global health authorities, including the FDA, EMA, and PMDA. Her comprehensive understanding of regulatory requirements has made her a valuable asset to these organizations.
Current Role as VP, Regulatory Affairs
In her current role as Vice President of Regulatory Affairs, Andeleeb Al Mobaraq-Dahy oversees the regulatory strategies for drug development. Her responsibilities include ensuring compliance with global health authority requirements, managing submissions, and coordinating with cross-functional teams. Through her leadership, the company has navigated complex regulatory landscapes efficiently. Her strategic input has been crucial in advancing the company's portfolio across various therapeutic areas.
Educational Background in Drug Innovation
Andeleeb Al Mobaraq-Dahy holds a master's degree in Drug Innovation from the University of Utrecht. This academic foundation has equipped her with a robust understanding of drug discovery and development processes. Her education in drug innovation complements her regulatory expertise, enabling her to contribute effectively to both drug discovery and R&D endeavors within the industry. Her background as a pharmacist further enhances her ability to develop and implement innovative regulatory strategies.
Achievements in Global Regulatory Submissions
Throughout her career, Andeleeb Al Mobaraq-Dahy has achieved numerous milestones in global regulatory submissions. She has successfully led submissions to major health authorities such as the FDA, EMA, and PMDA. Her expertise in navigating regulatory pathways has facilitated the approval of various therapeutic products, ranging from rare orphan diseases to common conditions. Her ability to develop comprehensive regulatory strategies has been critical in achieving these approvals.
Leadership in the Innovative Medicines Initiative (IMI)
Andeleeb Al Mobaraq-Dahy has played a pivotal role in the Innovative Medicines Initiative (IMI) project focused on optimizing the R&D of advanced therapy medicinal products (ATMP). In this capacity, she has collaborated with other pharmaceutical and biotechnology companies to enhance the development processes of ATMPs. Her leadership in this initiative underscores her commitment to advancing the field of medicinal products through innovation and collaboration.